1 completed, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Mitchell Cairo: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion alpha beta depletion - Acute Leukemia, Severe Aplastic Anemia | Phase 2 | Recruiting | Mitchell Cairo | 20 | 2021-04-01 | 2026-10-23 |
| Brentuximab for Newly Diagnosed Hodgkin Disease Brentuximab Vedotin, Doxorubicin, Vincristine - Hodgkin Lymphoma | Phase 2 | Completed | Mitchell Cairo | 40 | 2015-05-01 | 2023-10-26 |
Hodgkin Disease (2) · Anemia, Aplastic (1) · Anemia, Diamond-Blackfan (1) · Anemia, Sickle Cell (1) · Lymphoma, Non-Hodgkin (1) · Neutropenia, Severe Congenital, Autosomal Recessive 3 (1) · beta-Thalassemia (1)
Brentuximab Vedotin (1) · Doxorubicin (1) · Rituximab (1) · Vincristine (1) · liposomal doxorubicin (1)
United States (2)
Jessica Hochberg, MD (1) · Mitchell S Cairo (1)